Latest Us Market News

DorsaVi Limited reported a steep increase in its half-year loss to $3.6 million, driven by declining revenues and a sharp rise in operating costs, despite raising over $5 million in fresh capital.

Decidr AI Industries Ltd reported a $17.2 million loss for the half-year ending December 2025, reversing a prior profit, while completing full ownership of Decidr.ai and expanding into the US market with Sugarwork Inc.

Ovanti Limited announces a strategic leadership change in its US operations to boost its BNPL platform Flote’s commercialisation and prepare for a potential NASDAQ listing via SPAC.

StepChange Holdings Limited reports a strong half-year performance post-IPO, with $24.36 million in revenue and a net profit of $524,400, underpinned by key acquisitions and US expansion.

TZ Limited reported a $1.92 million loss for the half-year ending December 2025, with revenues of $5.4 million impacted by delayed US projects and integration challenges from its Keyvision acquisition. The company is banking on large tenders and expanding Microsoft data centre sales to drive recovery.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Cettire Limited reported a 2.8% revenue decline to $382.8 million and a net loss of $1.05 million for the half-year ended 31 December 2025, impacted by softer US demand and rising costs. Despite these headwinds, the company maintains a strong cash position and is focused on profitable growth.

Tungsten Mining is pursuing a US stock exchange listing to tap into deeper capital markets and strengthen ties with US government and industry stakeholders, complementing its existing ASX listing.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

Kip McGrath Education Centres Limited reported a 15.4% rise in profit after tax for the half-year ending December 2025, driven by pricing and operational efficiencies despite a 5% drop in lesson volumes. The company also declared a fully franked interim dividend and completed a share buyback amid leadership changes.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.